Cargando…

α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 Ameliorates Cognitive Impairment Induced by Chronic Intermittent Hypoxia

PURPOSE: Cognitive impairment is an important complication of obstructive sleep apnea (OSA). Chronic intermittent hypoxia (CIH), the main pathophysiological characteristics of OSA, is closely related to cognitive dysfunction and may be mediated by alpha-7 nicotinic acetylcholine receptors (α7nAChR)....

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Hui, Meng, Yanling, Liu, Dan, Qin, Zheng, Huang, Hong, Pan, Lei, Wang, Wei, Kang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123952/
https://www.ncbi.nlm.nih.gov/pubmed/34007230
http://dx.doi.org/10.2147/NSS.S296701
_version_ 1783693067241390080
author Shen, Hui
Meng, Yanling
Liu, Dan
Qin, Zheng
Huang, Hong
Pan, Lei
Wang, Wei
Kang, Jian
author_facet Shen, Hui
Meng, Yanling
Liu, Dan
Qin, Zheng
Huang, Hong
Pan, Lei
Wang, Wei
Kang, Jian
author_sort Shen, Hui
collection PubMed
description PURPOSE: Cognitive impairment is an important complication of obstructive sleep apnea (OSA). Chronic intermittent hypoxia (CIH), the main pathophysiological characteristics of OSA, is closely related to cognitive dysfunction and may be mediated by alpha-7 nicotinic acetylcholine receptors (α7nAChR). This study investigated the effects and clarified the mechanisms of α7nAChR on the cognitive function of mice with CIH. METHODS: Thirty CD-1 mice were randomly divided into room air (RA), CIH-2 weeks (CIH2W), and CIH-4 weeks (CIH4W) groups. Cognitive function was evaluated by novel object recognition (NOR) and Morris water maze (MWM) tests after exposure. Then, 104 CD-1 mice were exposed to CIH for 4 weeks and randomly divided into four groups: CIH4W (control), with dimethyl sulfoxide (DMSO) (sham), with α7nAChR-specific agonist PNU-282987 (PNU), and with α7nAChR-specific inhibitor methyllycaconitine and PNU-282987 (MLA+PNU). In addition to the evaluation of cognitive function, apoptotic bodies in the hippocampus were detected by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, changes in p-CREB and BDNF were detected by immunohistochemistry, while those of ERK1/2, CREB, PGC-1α, FNDC5, and BDNF were detected by Western blotting in the hippocampal tissues of the mice. RESULTS: Compared to the CIH2W and RA groups, the CIH4W group showed cognitive dysfunction in the NOR and MWM tests. The changes in cognitive dysfunction were alleviated by PNU-282987; furthermore, MLA pretreatment offset the effect. In hippocampal tissues, TUNEL assays showed decreased apoptotic cells, immunohistochemical staining showed increased expressions of p-CREB and BDNF. The expression levels of p-ERK1/2/t-ERK1/2, p-CREB/t-CREB, PGC-1α, FNDC5, and BDNF were increased after PNU-282987 injection. CONCLUSION: Four weeks of CIH caused cognitive dysfunction in mice. Activating α7nAChR might ameliorate this dysfunction by upregulating the ERK1/2/CREB signaling pathway; enhancing PGC-1α, FNDC5, and BDNF expression levels; and reducing cell apoptosis in the hippocampal tissue of mice.
format Online
Article
Text
id pubmed-8123952
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81239522021-05-17 α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 Ameliorates Cognitive Impairment Induced by Chronic Intermittent Hypoxia Shen, Hui Meng, Yanling Liu, Dan Qin, Zheng Huang, Hong Pan, Lei Wang, Wei Kang, Jian Nat Sci Sleep Original Research PURPOSE: Cognitive impairment is an important complication of obstructive sleep apnea (OSA). Chronic intermittent hypoxia (CIH), the main pathophysiological characteristics of OSA, is closely related to cognitive dysfunction and may be mediated by alpha-7 nicotinic acetylcholine receptors (α7nAChR). This study investigated the effects and clarified the mechanisms of α7nAChR on the cognitive function of mice with CIH. METHODS: Thirty CD-1 mice were randomly divided into room air (RA), CIH-2 weeks (CIH2W), and CIH-4 weeks (CIH4W) groups. Cognitive function was evaluated by novel object recognition (NOR) and Morris water maze (MWM) tests after exposure. Then, 104 CD-1 mice were exposed to CIH for 4 weeks and randomly divided into four groups: CIH4W (control), with dimethyl sulfoxide (DMSO) (sham), with α7nAChR-specific agonist PNU-282987 (PNU), and with α7nAChR-specific inhibitor methyllycaconitine and PNU-282987 (MLA+PNU). In addition to the evaluation of cognitive function, apoptotic bodies in the hippocampus were detected by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, changes in p-CREB and BDNF were detected by immunohistochemistry, while those of ERK1/2, CREB, PGC-1α, FNDC5, and BDNF were detected by Western blotting in the hippocampal tissues of the mice. RESULTS: Compared to the CIH2W and RA groups, the CIH4W group showed cognitive dysfunction in the NOR and MWM tests. The changes in cognitive dysfunction were alleviated by PNU-282987; furthermore, MLA pretreatment offset the effect. In hippocampal tissues, TUNEL assays showed decreased apoptotic cells, immunohistochemical staining showed increased expressions of p-CREB and BDNF. The expression levels of p-ERK1/2/t-ERK1/2, p-CREB/t-CREB, PGC-1α, FNDC5, and BDNF were increased after PNU-282987 injection. CONCLUSION: Four weeks of CIH caused cognitive dysfunction in mice. Activating α7nAChR might ameliorate this dysfunction by upregulating the ERK1/2/CREB signaling pathway; enhancing PGC-1α, FNDC5, and BDNF expression levels; and reducing cell apoptosis in the hippocampal tissue of mice. Dove 2021-05-11 /pmc/articles/PMC8123952/ /pubmed/34007230 http://dx.doi.org/10.2147/NSS.S296701 Text en © 2021 Shen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Shen, Hui
Meng, Yanling
Liu, Dan
Qin, Zheng
Huang, Hong
Pan, Lei
Wang, Wei
Kang, Jian
α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 Ameliorates Cognitive Impairment Induced by Chronic Intermittent Hypoxia
title α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 Ameliorates Cognitive Impairment Induced by Chronic Intermittent Hypoxia
title_full α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 Ameliorates Cognitive Impairment Induced by Chronic Intermittent Hypoxia
title_fullStr α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 Ameliorates Cognitive Impairment Induced by Chronic Intermittent Hypoxia
title_full_unstemmed α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 Ameliorates Cognitive Impairment Induced by Chronic Intermittent Hypoxia
title_short α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 Ameliorates Cognitive Impairment Induced by Chronic Intermittent Hypoxia
title_sort α7 nicotinic acetylcholine receptor agonist pnu-282987 ameliorates cognitive impairment induced by chronic intermittent hypoxia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123952/
https://www.ncbi.nlm.nih.gov/pubmed/34007230
http://dx.doi.org/10.2147/NSS.S296701
work_keys_str_mv AT shenhui a7nicotinicacetylcholinereceptoragonistpnu282987amelioratescognitiveimpairmentinducedbychronicintermittenthypoxia
AT mengyanling a7nicotinicacetylcholinereceptoragonistpnu282987amelioratescognitiveimpairmentinducedbychronicintermittenthypoxia
AT liudan a7nicotinicacetylcholinereceptoragonistpnu282987amelioratescognitiveimpairmentinducedbychronicintermittenthypoxia
AT qinzheng a7nicotinicacetylcholinereceptoragonistpnu282987amelioratescognitiveimpairmentinducedbychronicintermittenthypoxia
AT huanghong a7nicotinicacetylcholinereceptoragonistpnu282987amelioratescognitiveimpairmentinducedbychronicintermittenthypoxia
AT panlei a7nicotinicacetylcholinereceptoragonistpnu282987amelioratescognitiveimpairmentinducedbychronicintermittenthypoxia
AT wangwei a7nicotinicacetylcholinereceptoragonistpnu282987amelioratescognitiveimpairmentinducedbychronicintermittenthypoxia
AT kangjian a7nicotinicacetylcholinereceptoragonistpnu282987amelioratescognitiveimpairmentinducedbychronicintermittenthypoxia